Search research articles
Contact Us
Filters
Showing results (31-40 of 47) with videos related to
Page
of 5
Sort By:
Cancer Letters
|
November 27, 2024
PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer
Sakthivel Muniyan, Raghupathy Vengoji, Rama Krishna Nimmakayala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 28, 2020
Sildenafil Potentiates the Therapeutic Efficacy of Docetaxel in Advanced Prostate Cancer by Stimulating NO-cGMP Signaling
Sakthivel Muniyan, Satyanarayana Rachagani, Seema Parte, et al.
Bone Research
|
May 15, 2021
Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases
Navatha Shree Polavaram, Samikshan Dutta, Ridwan Islam, et al.
Cell Reports
|
July 20, 2022
Neuropilin-2 axis in regulating secretory phenotype of neuroendocrine-like prostate cancer cells and its implication in therapy resistance
Ridwan Islam, Juhi Mishra, Navatha Shree Polavaram, et al.
European Urology
|
July 7, 2020
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts
Mark C Markowski, Hao Wang, Rana Sullivan, et al.
Nature Communications
|
December 31, 2024
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial
Mark N Stein, Ecaterina E Dumbrava, Benjamin A Teply, et al.
JAMA Oncology
|
August 22, 2024
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial
Catherine H Marshall, Benjamin A Teply, Jiayun Lu, et al.
The Lancet. Oncology
|
December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
Benjamin A Teply, Hao Wang, Brandon Luber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 14, 2021
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)
Jonathan E Rosenberg, Karla A Ballman, Susan Halabi, et al.
Cancer Letters
|
November 8, 2023
Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TβRI expression
Massar Alsamraae, Diane Costanzo-Garvey, Benjamin A Teply, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 47) with videos related to
Sort By:
Page
of 5
Cancer Letters
|
November 27, 2024
PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer
Sakthivel Muniyan, Raghupathy Vengoji, Rama Krishna Nimmakayala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 28, 2020
Sildenafil Potentiates the Therapeutic Efficacy of Docetaxel in Advanced Prostate Cancer by Stimulating NO-cGMP Signaling
Sakthivel Muniyan, Satyanarayana Rachagani, Seema Parte, et al.
Bone Research
|
May 15, 2021
Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases
Navatha Shree Polavaram, Samikshan Dutta, Ridwan Islam, et al.
Cell Reports
|
July 20, 2022
Neuropilin-2 axis in regulating secretory phenotype of neuroendocrine-like prostate cancer cells and its implication in therapy resistance
Ridwan Islam, Juhi Mishra, Navatha Shree Polavaram, et al.
European Urology
|
July 7, 2020
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts
Mark C Markowski, Hao Wang, Rana Sullivan, et al.
Nature Communications
|
December 31, 2024
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial
Mark N Stein, Ecaterina E Dumbrava, Benjamin A Teply, et al.
JAMA Oncology
|
August 22, 2024
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial
Catherine H Marshall, Benjamin A Teply, Jiayun Lu, et al.
The Lancet. Oncology
|
December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
Benjamin A Teply, Hao Wang, Brandon Luber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 14, 2021
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)
Jonathan E Rosenberg, Karla A Ballman, Susan Halabi, et al.
Cancer Letters
|
November 8, 2023
Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TβRI expression
Massar Alsamraae, Diane Costanzo-Garvey, Benjamin A Teply, et al.
Page
of 5